Table 2.

Current Antiretroviral Treatment

	All treated subjects (N = 49) N (%)	Protease inhibitor-based regimens (N = 28) N (%)	Nonprotease inhibitor-based regimens (N = 21) N (%)
Nucleoside reverse transcriptase inhibitors
Abacavir	11 (22%)	6 (21%)	5 (24%)
Emtricitabine	12 (24%)	9 (32%)	3 (14%)
Lamivudine	28 (57%)	15 (54%)	13 (62%)
Stavudine	2 (4%)	1 (4%)	1 (5%)
Tenofovir	20 (41%)	13 (46%)	7 (33%)
Zidovudine	21 (43%)	11 (39%)	10 (48%)
Protease inhibitors
Atazanavir	6 (12%)	6 (21%)	0
Fosamprenavir	2 (4%)	2 (7%)	0
Lopinavir-ritonavir	20 (41%)	20 (71%)	0
Nelfinavir	5 (10%)	5 (18%)	0
Ritonavir-boosted PI	20 (41%)	20 (71%)	0
Nonnucleoside reverse transciptase inhibitors
Efavirenz	19 (39%)	0	19 (91%)
Nevirapine	1 (2%)	0	1 (5%)